Freeze-drying and Annex 1: New requirements for sterile processes

Regulatory requirements with global impact

The production of sterile medicines is subject to high regulatory requirements. Freeze-drying is considered a critical process step, because maximum sterility is uncompromisingly required here. Sensitive active ingredients must be optimally protected to preserve their quality. Even small errors or contamination can jeopardize product safety and product quality and have regulatory consequences. This is why freeze-drying as part of the aseptic production line is also at the center of the discussion about sterile manufacturing processes.

Requirements of Annex 1 for freeze-drying

The revised version of Annex 1 of the EU GMP Guidelines sets clear standards for the production of sterile medicinal products. Especially in freeze-drying, it tightens the specifications for the sterilization of parts that come into contact with the product, the validation of sterilization cycles, and the continuous monitoring and documentation of critical process parameters such as temperature, pressure, and time. The aim is to minimise contamination risks and ensure complete traceability of all process steps. For many companies, this means reviewing existing systems and processes and, if necessary, adapting them to reliably implement the new requirements.

Challenges especially in the US market

The revision of Annex 1 has a global impact. In the US market, too, the pharmaceutical industry is dealing intensively with the stricter requirements. Although the regulations of the FDA primarily apply there, the harmonization of international standards and the global networking of production and supply chains mean that Annex 1 is increasingly relevant for US manufacturers as well.

Many U.S. companies are therefore faced with the task of retrofitting their processes in and around freeze-drying plants to ensure sterilization, process monitoring, and the minimization of manual intervention. Barrier technologies including isolators and restricted access barrier systems are increasingly being used to ensure a clear separation between personnel and product. Depending on the type of product, this serves both to protect the product from contamination and to protect personnel from highly potent substances. 

At the same time, the importance of digital traceability is increasing, as process data must be collected, stored and documented in real time to meet audits and international compliance requirements.

Innovative solutions for Annex 1-compliant freeze-drying

Optima supports pharmaceutical companies worldwide with customized solutions that are Annex 1 compliant. The basis for this is the combination of validated processes, automation, and digital process control. Fully automated loading and unloading processes reduce manual intervention, precise process monitoring ensures compliance with all critical parameters, and flexible barrier technologies protect particularly sensitive production steps.

The filtration of process gases with automatic filter integrity control and corresponding integrity tests of the entire plant are also part of the systems. Comprehensive leak tests, from bellows tests to mass spectroscopy for silicone oil detection, complete the overall concept.

This enables manufacturers to efficiently implement the new requirements, minimize risks, and increase productivity at the same time – both in Europe and in the US market.